TAN-118 / Shanghai Thederma Pharmaceuticals - LARVOL DELTA

A randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the safety, tolerability, preliminary efficacy based on the modified Mayo score, and pharmacokinetics/pharmacodynamics of multiple-dose 8-week induction treatment with TAN-118 tablets in patients with moderate to severe active ulcerative colitis. (ChiCTR) - P2 | N=80 | Not yet recruiting | Sponsor: Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine; Shanghai Thederma Pharmaceutical Technology Co., Ltd

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CYP1A1 • IL23A

A randomized, double-blind, placebo-controlled Phase IIa exploratory proof-of-concept (PoC) clinical trial to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of TAN-118 tablets in patients with active ulcerative colitis. (ChiCTR) - P2 | N=10 | Not yet recruiting | Sponsor: Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine; Shanghai Thederma Pharmaceutical Technology Co., Ltd

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CYP1A1 • IL23A

Phase I clinical trial to evaluate the local pharmacokinetics of TAN-118 tablets in healthy adult subjects (ChiCTR) - P1 | N=6 | Sponsor: Nanjing First Hospital; Shanghai Thederma Pharmaceutical Technology Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

To evaluate the safety and tolerability of TAN-118 tablets in healthy adult subjects (ChiCTR) - P1 | N=92 | Not yet recruiting | Sponsor: Nanjing First Hospital; Shanghai Thederma Pharmaceutical Technology Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease